BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 9179282)

  • 1. Treatment of fungal and other opportunistic infections in immunocompromised patients.
    Wade JC
    Leukemia; 1997 May; 11 Suppl 4():S38-9. PubMed ID: 9179282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fungal infections in children with malignant disease].
    Michel G
    Arch Pediatr; 2011 May; 18 Suppl 1():S3-7. PubMed ID: 21596284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fungal infections in iatrogenically compromised hosts.
    Rex JH; Walsh TJ; Anaissie EJ
    Adv Intern Med; 1998; 43():321-71. PubMed ID: 9506187
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prophylaxis against mycoses in neutropenic patients].
    Arning M; Aul C
    Mycoses; 1994; 37 Suppl 2():70-6. PubMed ID: 7541892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of immunocompromised patients with evidence of an invasive mycosis.
    Walsh TJ
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fungal infections in cancer patients: an escalating problem.
    Samonis G; Bafaloukos D
    In Vivo; 1992; 6(2):183-93. PubMed ID: 1525339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungal infections in patients with cancer.
    Anaissie EJ; Bodey GP
    Pharmacotherapy; 1990; 10(6 ( Pt 3)):164S-169S. PubMed ID: 2075117
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention of fungal infections in children and adolescents with cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Systemic fungal infections in immunocompromised patients].
    Zupanić-Krmek D; Nemet D
    Acta Med Croatica; 2004; 58(4):251-61. PubMed ID: 15700680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mycoses in surgical patients -- review of the literature.
    Holzheimer RG; Dralle H
    Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fungal infections in the immunocompromised host.
    Hawkins C; Armstrong D
    Clin Haematol; 1984 Oct; 13(3):599-630. PubMed ID: 6388935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
    Doubek M; Mayer J; Horký D; Doubek J; Rácil Z; Vorlícek J
    Vnitr Lek; 2002 Mar; 48(3):248-54. PubMed ID: 11968587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases.
    Walsh TJ; Lee JW; Roilides E; Pizzo PA
    Curr Opin Oncol; 1992 Aug; 4(4):647-55. PubMed ID: 1511021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fungal infections in transplantation patients].
    Colomba C; Antinori S
    Recenti Prog Med; 2003 Nov; 94(11):516-28. PubMed ID: 14679922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for managing systemic fungal infection and the place of itraconazole.
    Potter M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.
    Walsh TJ; Hiemenz JW; Anaissie E
    Infect Dis Clin North Am; 1996 Jun; 10(2):365-400. PubMed ID: 8803625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal prophylaxis in bone marrow transplantation.
    Milliken ST; Powles RL
    Rev Infect Dis; 1990; 12 Suppl 3():S374-9. PubMed ID: 2184515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.